TriangleStereotactic Body Radiation Therapy (NCT06843551)
Stereotactic Body Radiation Therapy trial for Metastatic Pancreatic Ductal Adenocarcinoma (NCT06843551). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with microsatellite-stable metastatic pancreatic ductal adenocarcinoma progressing after at least one systemic treatment. Liver involvement must not exceed 25%.
The idea: radiation damages cancer cells, followed within seven days by botensilimab and balstilimab to support immune attack. Intravenous botensilimab is given every six weeks for four doses; balstilimab every two weeks for up to one year. A previously unirradiated lesion suitable for biopsy is required. Researchers measure disease control.
This phase 2 study plans 20 patients. Benjamin Spieler leads at University of Miami, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.